A Study to Examine Anktiva for the Treatment of COVID-19.

Part of paid clinical trials in El Segundo, California.

Sponsor
ImmunityBio, Inc.
Study ID
NCT07123727
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 70 Years
Healthy Volunteers
Not accepted

Interventions

  • Anktiva — DRUG
    600ug of NAI administered subcutaneously

Study Details

This study will examine the safety and effectiveness of Anktiva in treating patients with Long COVID-19 which is defined as persistent symptoms of a COVID-19 infection that remain after the infection is over.

Key Dates

Start date
Sep 4, 2025
Status verified
Aug 2025
Primary completion
Jul 31, 2026
Completion
Jul 31, 2026

Study Design

Enrollment
40 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: N-803

Primary Outcome Measure

Incidence of treatment emergent adverse events (TEAEs) through 30 days post final study drug administration. [ Time Frame: Through 30 days post final study drug administration. ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Chan Soon-Schiong Institute for Medicine (CSSIFM)El SegundoCalifornia90245
Jaya Gill
[email protected]
310-955-4500
Chaitali Nangia, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in El Segundo, CA

By condition
COVID-19 / long COVID
By specialty
Infectious disease
By research site
Chan Soon-Schiong Institute for Medicine (CSSIFM)· El Segundo, CA

Related Studies